HDL and immunomodulation: An emerging role of HDL against atherosclerosis

Immunology and Cell Biology

Volumn 88, Issue 3, 2010, Pages 285-290

  Yu, Bi Lian ^a   Wang, Shu Hui ^a   Peng, Dao Quan ^a   Zhao, Shui Ping ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ABC TRANSPORTER A1; ABC TRANSPORTER G1; APOLIPOPROTEIN A1; B LYMPHOCYTE RECEPTOR; GAMMA INTERFERON; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; IMMUNOGLOBULIN; LIPOPOLYSACCHARIDE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LYSOPHOSPHATIDIC ACID; REGULATOR PROTEIN; SPHINGOMYELIN; T LYMPHOCYTE RECEPTOR; T6 ANTIGEN; THROMBOCYTE ACTIVATING FACTOR;

ADAPTIVE IMMUNITY; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; ANTIGEN SPECIFICITY; ATHEROSCLEROSIS; CARDIOVASCULAR INFLAMMATION; CD4+ T LYMPHOCYTE; CELL ACTIVATION; CELL ADHESION; CELL DIFFERENTIATION; CELL FUNCTION; CELL MEMBRANE; CELL MIGRATION; CELL PROLIFERATION; CHOLESTEROL BLOOD LEVEL; COMPLEMENT ACTIVATION; CYTOKINE RELEASE; DENDRITIC CELL; DISEASE COURSE; HISTOCOMPATIBILITY COMPLEX; HUMAN; IMMUNE RESPONSE; IMMUNOBLAST; IMMUNOMODULATION; INNATE IMMUNITY; LIPID OXIDATION; LIPID RAFT; LIPOPROTEIN METABOLISM; MACROPHAGE; MONOCYTE; NONHUMAN; PLASMA PROTEIN BINDING; PROTEIN FUNCTION; PROTEIN LOCALIZATION; REMISSION; REVIEW; SIGNAL TRANSDUCTION;

1-ALKYL-2-ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ADAPTIVE IMMUNITY; ANIMALS; ATHEROSCLEROSIS; CHOLESTEROL, HDL; DENDRITIC CELLS; HUMANS; IMMUNE SYSTEM DISEASES; IMMUNITY, INNATE; IMMUNOMODULATION; INFLAMMATION; MEMBRANE MICRODOMAINS; MONOCYTES; RHEUMATIC FEVER;

EID: 77949873805     PISSN: 08189641     EISSN: 14401711     Source Type: Journal    
DOI: 10.1038/icb.2009.112     Document Type: Review

References (72)

1. Ansell BJ, Watson KE, Fogelman AM, Navab M, Fonarow GC. High-density lipoprotein function recent advances. J Am Coll Cardiol 2005; 46: 1792-1798.
2. Mineo C, Yuhanna IS, Quon MJ, Shaul PW. High density lipoprotein induced endothelial nitric-oxide synthase activation is mediated by Akt and MAP kinases. J Biol Chem 2003; 278: 9142-9149.
3. Mackness MI, Durrington PN. HDL, its enzymes and its potential to influence lipid peroxidation. Atherosclerosis 1995; 115: 243-253.
4. Desai K, Bruckdorfer KR, Hutton RA, Owen JS. Binding of apoE-rich high density lipoprotein particles by saturable sites on human blood platelets inhibits agonistinduced platelet aggregation. J Lipid Res 1989; 30: 831-840.
5. Svenungsson E, Gunnarsson I, Fei GZ, Lundberg IE, Klareskog L, Frostegård J. Elevated triglycerides and low levels of high-density lipoprotein as markers of disease activity in association with up-regulation of the tumor necrosis factor alpha/tumor necrosis factor receptor system in systemic lupus erythematosus. Arthritis Rheum 2003; 48: 2533-2540.
6. van Halm VP, van Denderen JC, Peters MJ, Twisk JW, van der Paardt M, van der Horst- Bruinsma IE et al. Increased disease activity is associated with a deteriorated lipid profile in patients with ankylosing spondylitis. Ann Rheum Dis 2006; 65: 1473-1477.
7. van Halm VP, Nielen MM, Nurmohamed MT, van Schaardenburg D, Reesink HW, Voskuyl AE et al. Lipids and inflammation: serial measurements of the lipid profile of blood donors who later developed rheumatoid arthritis. Ann Rheum Dis 2007; 66: 184-188.
8. Libby P. Inflammation in atherosclerosis. Nature 2002; 420: 868-874.
9. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 1999; 340: 115-126.
10. Shah PK. Mechanisms of plaque vulnerability and rupture. J Am Coll Cardiol 2003; 41: 15S-22S.
11. Hansson GK, Libby P, Schönbeck U, Yan ZQ. Innate and adaptive immunity in the pathogenesis of atherosclerosis. Circ Res 2002; 91: 281-291.
12. Binder CJ, Chang MK, Shaw PX, Miller YI, Hartvigsen K, Dewan A et al. Innate and acquired immunity in atherogenesis. Nat Med 2002; 8: 1218-1226.
13. Kiechl S, Lorenz E, Reindl M, Wiedermann CJ, Oberhollenzer F, Bonora E et al. Toll-like receptor 4 polymorphisms and atherogenesis. N Engl J Med 2002; 347: 185-192.
14. Stoll LL, Denning GM, Weintraub NL. Potential role of endotoxin as a proinflammatory mediator in atherosclerosis. Arterscler Thromb Vasc Biol 2004; 24: 2227-2236.
15. Palinski W, Witztum JL. Immune responses to oxidative neoepitopes on LDL and phospholipids modulate the development of atherosclerosis. J InternMed 2000; 247: 371-380.
16. van Puijvelde GH, van Es T, van Wanrooij EJ, Habets KL, de Vos P, van der Zee R et al. Induction of oral tolerance to HSP60 or an HSP60-peptide activates T cell regulation and reduces atherosclerosis. Arterioscler Thromb Vasc Biol 2007; 27: 2677-2683.
17. Zhou X, Hansson GK. Immunomodulation and vaccination for atherosclerosis. Expert Opin Biol Ther 2004; 4: 599-612.
18. Ansell BJ. Targeting the anti-inflammatory effects of high-density lipoprotein. Am J Cardiol 2007; 100: n3-n9.
19. Ulevitch RJ, Johnston AR, Weinstein DB. New function for high density lipoproteins. Their participation in intravascular reactions of bacterial lipopolysaccharides. J Clin Invest 1979; 64: 1516-1524.
20. Ulevitch RJ, Johnston AR, Weinstein DB. New function for high density lipoproteins. Isolation and characterization of a bacterial lipopolysaccharide- high density lipoprotein complex formed in rabbit plasma. J Clin Invest 1981; 67: 827-837.
21. Levine DM, Parker TS, Donnelly TM, Walsh A, Rubin AL. In vivo protection against endotoxin by plasma high density lipoprotein. Proc Natl Acad Sci USA 1993; 90: 12040-12044.
22. Cavaillon JM, Fitting C, Haeffner-Cavaillon N, Kirsch SJ, Warren HS. Cytokine response by monocytes and macrophages to free and lipoprotein-bound lipopolysaccharide. Infect Immun 1990; 58: 2375-2382.
23. Grunfeld C, Feingold KR. HDL and innate immunity: a tale of two apolipoproteins. J Lipid Res 2008; 49: 1605-1606.
24. Wang Y, Zhu X, Wu G, Shen L, Chen B. Effect of lipid-bound apoA-I cysteine mutants on lipopolysaccharide-induced endotoxemia in mice. J Lipid Res 2008; 49: 1640-1645.
25. Marcel YL, Kiss RS. Structure-function relationships of apolipoprotein A-I: a flexible protein with dynamic lipid associations. Curr Opin Lipidol 2003; 14: 151-157.
26. Vercellotti GM, Hammerschmidt DE, Craddock PR, Jacob HS. Activation of plasma complement by perfluorocarbon artificial blood: probable mechanism of adverse pulmonary reactions in treated patients and rationale for corticosteroids prophylaxis. Blood 1982; 59: 1299-1304.
27. Kent KM, Cleman MW, Cowley MJ, Forman MB, Jaffe CC, Kaplan M et al. Reduction of myocardial ischemia during percutaneous transluminal coronary angioplasty with oxygenated Fluosol. Am J Cardiol 1990; 66: 279-284.
28. Moghimi SM, Hunter AC, Dadswell CM, Savay S, Alving CR, Szebeni J. Causative factors behind poloxamer 188 (Pluronic F68, Flocor)-induced complement activation in human sera. A protective role against poloxamer-mediated complement activation by elevated serum lipoprotein levels. Biochim Biophys Acta 2004; 1689: 103-113.
29. Moein Moghimi S, Hamad I, Bünger R, Andresen TL, Jørgensen K, Hunter AC et al. Activation of the human complement system by cholesterol-rich and PEGylated liposomes-modulation of cholesterol-rich liposome-mediated complement activation by elevated serum LDL and HDL levels. J Liposome Res 2006; 16: 167-174.
30. Vaisar T, Pennathur S, Green PS, Gharib SA, Hoofnagle AN, Cheung MC et al. Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL. J Clin Invest 2007; 117: 746-756.
31. Rezaee F, Casetta B, Levels JH, Speijer D, Meijers JC. Proteomic analysis of highdensity lipoprotein. Proteomics 2006; 26: 721-730.
32. Garlanda C, Bottazzi B, Bastone A, Mantovani A. Pentraxins at the crossroads between innate immunity, inflammation, matrix deposition, and female fertility. Annu Rev Immunol 2005; 23: 337-366.
33. Garlanda C, Hirsch E, Bozza S, Salustri A, De Acetis M, Nota R et al. Non-redundant role of the long pentraxin PTX3 in antifungal innate immune response. Nature 2002; 420: 182-186.
34. Norata GD, Marchesi P, Pirillo A, Uboldi P, Chiesa G, Maina V et al. Long pentraxin 3, a key component of innate immunity, is modulated by high-density lipoproteins in endothelial cells. Arterioscler Thromb Vasc Biol 2008; 28: 925-931.
35. Gustin C, Delaive E, Dieu M, Calay D, Raes M. Upregulation of pentraxin-3 in human endothelial cells after lysophosphatidic acid exposure. Arterioscler Thromb Vasc Biol 2008; 28: 491-497.
36. Yvan-Charvet L, Welch C, Pagler TA, Ranalletta M, Lamkanfi M, Han S et al. Increased inflammatory gene expression in ABC transporter-deficient macrophages: free cholesterol accumulation, increased signaling via toll-like receptors, and neutrophil infiltration of atherosclerotic lesions. Circulation 2009; 118: 1837-1847.
37. Bensinger SJ, Bradley MN, Joseph SB, Zelcer N, Janssen EM, Hausner MA et al. LXR signaling couples sterol metabolism to proliferation in the acquired immune response. Cell 2008; 134: 97-111.
38. Wilhelm AJ, Zabalawi M, Grayson JM, Weant AE, Major AS, Owen J et al. Apolipoprotein A-I and its role in lymphocyte cholesterol homeostasis and autoimmunity. Arterioscler Thromb Vasc Biol 2009; 29: 843-849.
39. Randolph GJ, Beaulieu S, Lebecque S, Steinman RM, Muller WA. Differentiation of monocytes into dendritic cells in a model of transendothelial trafficking. Science 1998; 282: 480-483.
40. Randolph GJ, Inaba K, Robbiani DF, Steinman RM, Muller WA. Differentiation of phagocytic monocytes into lymph node dendritic cells in vivo. Immunity 1999; 11: 753-761.
41. Randolph GJ. Emigration of monocyte-derived cells to lymph nodes during resolution of inflammation and its failure in atherosclerosis. Curr Opin Lipidol 2008; 19: 462-468.
42. Llodrá J, Angeli V, Liu J, Trogan E, Fisher EA, Randolph GJ. Emigration of monocytederived cells from atherosclerotic lesions characterizes regressive, but not progressive, plaques. Proc Natl Acad Sci USA 2004; 101: 11779-11784.
43. Kim KD, Lim HY, Lee HG, Yoon DY, Choe YK, Choi I et al. Apolipoprotein A-I induces IL-10 and PGE2 production in human monocytes and inhibits dendritic cell differentiation and maturation. Biochem Biophys Res Commun 2005; 338: 1126-1136.
44. Angeli V, Llodrá J, Rong JX, Satoh K, Ishii S, Shimizu T et al. Dyslipidemia associated with atherosclerotic disease systemically alters dendritic cell mobilization. Immunity 2004; 21: 561-574.
45. Rong JX, Li J, Reis ED, Choudhury RP, Dansky HM, Elmalem VI et al. Elevating highdensity lipoprotein cholesterol in apolipoprotein E-deficient mice remodels advanced atherosclerotic lesions by decreasing macrophage and increasing smooth muscle cell content. Circulation 2001; 104: 2447-2452.
46. Quarck R, De Geest B, Stengel D, Mertens A, Lox M, Theilmeier G et al. Adenovirusmediated gene transfer of human platelet-activating factor-acetylhydrolase prevents injury-induced neointima formation and reduces spontaneous atherosclerosis in apolipoprotein E-deficient mice. Circulation 2001; 103: 2495-2500.
47. Simons K, Ikonen E. Functional rafts in cell membranes. Nature 1997; 387: 569-572.
48. Poloso NJ, Roche PA. Association of MHC class II-peptide complexes with plasma membrane lipid microdomains. Curr Opin Immunol 2004; 16: 103-107.
49. Brown DA, London E. Functions of lipid rafts in biological membranes. Annu Rev Cell Dev Biol 1998; 14: 111-136.
50. Zidovetzki R, Levitan I. Use of cyclodextrins to manipulate plasma membrane cholesterol content: evidence, misconceptions and control strategies. Biochim Biophys Acta 2007; 1768: 1311-1324.
51. Sharma P, Varma R, Sarasij RC, Ira, Gousset K, Krishnamoorthy G et al. Nanoscale organization of multiple GPI-anchored proteins in living cell membranes. Cell 2004; 116: 577-589.
52. Chichili GR, Rodgers W. Clustering of membrane raft proteins by the actin cytoskeleton. J Biol Chem 2007; 282: 36682-36691.
53. Lenne PF, Wawrezinieck L, Conchonaud F, Wurtz O, Boned A, Guo XJ et al. Dynamic molecular confinement in the plasma membrane by microdomains and the cytoskeleton meshwork. EMBO J 2006; 25: 3245-3256.
54. Kenworthy AK. Have we become overly reliant on lipid rafts? Talking point on the involvement of lipid rafts in T-cell activation. EMBO Rep 2008; 9: 531-535.
55. Ishiwata H, Sato SB, Vertut-Doi A, Hamashima Y, Miyajima K. Cholesterol derivative of poly (ethylene glycol) inhibits clathrin-independent, but not clathrin-dependent endocytosis. Biochim Biophys Acta 1997; 1359: 123-135.
56. Kay JG, Murray RZ, Pagan JK, Stow JL. Cytokine secretion via cholesterol rich lipid raft associated SNAREs at the phagocytic cup. J Biol Chem 2006; 281: 11949-11954.
57. Koseki M, Hirano K, Masuda D, Ikegami C, Tanaka M, Ota A et al. Increased lipid rafts and accelerated lipopolysaccharide-induced tumor necrosis factor-alpha secretion in Abca1-deficient macrophages. J Lipid Res 2007; 48: 299-306.
58. Zhu X, Lee JY, Timmins JM, Brown JM, Boudyguina E, Mulya A et al. Increased cellular free cholesterol in macrophage-specific Abca1 knock-out mice enhances pro-inflammatory response of macrophages. J Biol Chem 2008; 283: 22930-22941.
59. Anderson HA, Hiltbold EM, Roche PA. Concentration of MHC class II molecules in lipid rafts facilitates antigen presentation. Nat Immunol 2000; 1: 156-162.
60. Setterblad N, Becart S, Charron D, Mooney N. B cell lipid rafts regulate both peptidedependent and peptide-independent APC-T cell interaction. J Immunol 2004; 173: 1876-1886.
61. Eren E, Yates J, Cwynarski K, Preston S, Dong R, Germain C et al. Location of major histocompatibility complex class II molecules in rafts on dendritic cells enhances the efficiency of T-cell activation and proliferation. Scand J Immunol 2006; 63: 7-16.
62. Cao X, Sugita M, Van Der Wel N, Lai J, Rogers RA, Peters PJ et al. CD1 molecules efficiently present antigen in immature dendritic cells and traffic independently of MHC class II during dendritic cell maturation. J Immunol 2002; 169: 4770-4777.
63. De Libero G, Mori L. Recognition of lipid antigens by T cells. Nat Rev Immunol 2005; 5: 485-496.
64. Sloma I, Zilber MT, Vasselon T, Setterblad N, Cavallari M, Mori L et al. Regulation of CD1a surface expression and antigen presentation by invariant chain and lipid rafts. J Immunol 2008; 180: 980-987.
65. Oram JF, Lawn RM, Garvin MR, Wade DP. ABCA1 is the cAMP-inducible apolipoprotein receptor that mediates cholesterol secretion from macrophages. J Biol Chem 2000; 275: 34508-34511.
66. Wang N, Lan D, Chen W, Matsuura F, Tall AR. ATP-binding cassette transporters G1 and G4 mediate cellular cholesterol efflux to high-density lipoproteins. Proc Natl Acad Sci USA 2004; 101: 9774-9779.
67. Mendez AJ, Lin G, Wade DP, Lawn RM, Oram JF. Membrane lipid domains distinct from cholesterol/sphingomyelin-rich rafts are involved in the ABCA1-mediated lipid secretory pathway. J Biol Chem 2001; 276: 3158-3166.
68. Puff N, Lamazière A, Seigneuret M, Trugnan G, Angelova MI. HDLs induce raft domain vanishing in heterogeneous giant vesicles. Chem Phys Lipids 2005; 133: 195-202.
69. Gaus K, Kritharides L, Schmitz G, Boettcher A, Drobnik W, Langmann T et al. Apolipoprotein A-1 interaction with plasma membrane lipid rafts controls cholesterol export from macrophages. FASEB J 2004; 18: 574-576.
70. Landry YD, Denis M, Nandi S, Bell S, Vaughan AM, Zha X. ATP-binding cassette transporter A1 expression disrupts raft membrane microdomains through its ATPaserelated functions. J Biol Chem 2006; 281: 36091-36101.
71. Murphy AJ, Woollard KJ, Hoang A, Mukhamedova N, Stirzaker RA, McCormick SP et al. High-density lipoprotein reduces the human monocyte inflammatory response. Arterioscler Thromb Vasc Biol 2008; 28: 2071-2077.
72. Shinkai H. Cholesteryl ester transfer protein inhibitors as high-density lipoprotein raising agents. Expert Opin Ther Pat 2009; 19: 1229-1237.